Coeptis Therapeutics Hldgs Inc (COEP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2025 | 06-2025 | 03-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -10,654 | -7,756 | -3,421 | -10,877 | -7,866 |
| Depreciation Amortization | 1,432 | 1,078 | 395 | 1,217 | 901 |
| Accounts receivable | -83 | -30 | N/A | N/A | 0 |
| Accounts payable and accrued liabilities | -482 | -241 | -149 | -150 | -286 |
| Other Working Capital | -1,570 | -990 | -221 | -125 | -81 |
| Other Operating Activity | 4,442 | 3,175 | 1,029 | 3,286 | 2,119 |
| Operating Cash Flow | $-6,915 | $-4,763 | $-2,366 | $-6,649 | $-5,213 |
| Cash Flows From Investing Activities | |||||
| Other Investing Activity | 0 | 0 | 0 | 0 | -100 |
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $-100 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 990 | 990 | 990 | 1,850 | 1,850 |
| Debt Repayment | -219 | -219 | -219 | -651 | -588 |
| Common Stock Issued | 5,065 | 1 | 0 | 600 | 500 |
| Other Financing Activity | 5,455 | 5,455 | 5,330 | 3,914 | 3,219 |
| Financing Cash Flow | $11,291 | $6,227 | $6,102 | $5,713 | $4,981 |
| Beginning Cash Position | 533 | 533 | 533 | 1,469 | 1,469 |
| End Cash Position | 4,909 | 1,997 | 4,268 | 533 | 1,138 |
| Net Cash Flow | $4,376 | $1,464 | $3,736 | $-936 | $-332 |
| Free Cash Flow | |||||
| Operating Cash Flow | -6,915 | -4,763 | -2,366 | -6,649 | -5,213 |
| Free Cash Flow | -6,915 | -4,763 | -2,366 | -6,649 | -5,213 |